Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in Incomplete Revascularization Post-PCI
NCT01442038Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2011
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of ranolazine in Angina Pectoris (AP), coronary artery disease (CAD), sponsored by Gilead Sciences. Started Oct 2011; status: completed.
02
Drugs
ranolazine
03
Conditions
Angina Pectoris (AP)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01442038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01442038.